

Fu-Quan Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1297920/publications.pdf>

Version: 2024-02-01

33
papers

564
citations

687363

13
h-index

677142

22
g-index

34
all docs

34
docs citations

34
times ranked

793
citing authors

#	ARTICLE	IF	CITATIONS
1	Silencing IQGAP1 alleviates hepatic fibrogenesis via blocking bone marrow mesenchymal stromal cell recruitment to fibrotic liver. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 471-483.	5.1	5
2	Dual Targeting of Angiotensin II and von Willebrand Factor by microRNA-671-5p Attenuates Liver Angiogenesis and Fibrosis. <i>Hepatology Communications</i> , 2022, 6, 1425-1442.	4.3	6
3	An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension. <i>Cell Reports Medicine</i> , 2022, 3, 100563.	6.5	13
4	Practice guidance for the use of terlipressin for liver cirrhosis-related complications. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210982.	3.2	8
5	Neutrophil recruitment mediated by sphingosine 1-phosphate (S1P)/S1P receptors during chronic liver injury. <i>Cellular Immunology</i> , 2021, 359, 104243.	3.0	20
6	Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. <i>World Journal of Gastroenterology</i> , 2021, 27, 416-427.	3.3	6
7	Hepatic parenchyma and vascular blood flow changes after TIPS with spectral CT iodine density in HBV-related liver cirrhosis. <i>Scientific Reports</i> , 2021, 11, 10535.	3.3	4
8	Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome. <i>Frontiers in Immunology</i> , 2020, 11, 1149.	4.8	59
9	Cannabinoid Receptor 1/miR-30b-5p Axis Governs Macrophage NLRP3 Expression and Inflammasome Activation in Liver Inflammatory Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 725-738.	5.1	22
10	Transjugular intrahepatic portosystemic shunt and splenectomy are more effective than endoscopic therapy for recurrent variceal bleeding in patients with idiopathic noncirrhotic portal hypertension. <i>World Journal of Clinical Cases</i> , 2020, 8, 1871-1877.	0.8	6
11	Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 301-307.	0.9	27
12	Iodine density Changes in Hepatic and Splenic Parenchyma in Liver Cirrhosis with Dual Energy CT (DECT): A Preliminary Study. <i>Academic Radiology</i> , 2019, 26, 872-877.	2.5	13
13	Correlation analysis of collagen proportionate area in Budd-Chiari syndrome: A preliminary clinicopathological study. <i>World Journal of Clinical Cases</i> , 2019, 7, 130-136.	0.8	0
14	Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 3282-3288.	0.8	1
15	Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 323-330.	0.9	64
16	Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis: An analysis of data from CHES-1601 trial. <i>Journal of Hepatology</i> , 2018, 68, 210-211.	3.7	13
17	Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 496-504.	2.0	13
18	Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHES1701): a prospective multicenter study. <i>EBioMedicine</i> , 2018, 36, 151-158.	6.1	64

#	ARTICLE	IF	CITATIONS
19	Benefits of Early Treatment for Patients with Hepatic Myelopathy Secondary to TIPS: A Retrospective Study in Northern China. <i>Scientific Reports</i> , 2018, 8, 15184.	3.3	5
20	Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-9.	1.9	7
21	Association of hepatic vein Lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death. <i>Journal of International Medical Research</i> , 2017, 45, 1148-1157.	1.0	0
22	Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1372-1382.	2.0	22
23	Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein. <i>Scientific Reports</i> , 2017, 7, 10868.	3.3	17
24	Pathological Predictors of Shunt Stenosis and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	7
25	Tanshinone IIA Protects against Dextran Sulfate Sodium- (DSS-) Induced Colitis in Mice by Modulation of Neutrophil Infiltration and Activation. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-10.	4.0	24
26	Evaluation of mid- and long-term efficacy of shunt limiting for hepatic myelopathy after transjugular intrahepatic portosystemic shunt. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 440-446.	1.5	7
27	Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis. <i>Scientific Reports</i> , 2016, 6, 33069.	3.3	11
28	Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial. <i>Scientific Reports</i> , 2016, 6, 21011.	3.3	32
29	Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome with diffuse occlusion of hepatic veins. <i>Scientific Reports</i> , 2016, 6, 36380.	3.3	29
30	Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol. <i>World Journal of Gastroenterology</i> , 2015, 21, 9544.	3.3	9
31	Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. <i>World Journal of Gastroenterology</i> , 2015, 21, 12439.	3.3	22
32	Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome. <i>World Journal of Gastroenterology</i> , 2015, 21, 2413.	3.3	12
33	Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 11835.	3.3	16